RFK Jr. declared war on chronic disease. What should be a priority?

How would you make the U.S. healthier? Here are nine ways to tackle the growing epidemic

May 20, 2025 Check out STAT+

Sponsored By

Mike Reddy for STAT STAT+ | RFK Jr. declared war on chronic disease. First comes the battle over priorities A report on the chronic disease epidemic is due soon. Use our interactive dataset of nine issues to see how your priorities match the MAHA commission's. By Isabella Cueto and J. Emory Parker STAT+ | FDA will limit Covid vaccines to people over 65 or at high risk of serious illness, leaders say FDA leaders said recommending universal vaccination against Covid-19 is out of step with the rest of the world and may no longer be needed By Helen Branswell, Matthew Herper, and Lizzy Lawrence STAT+ | Trump administration lays out more details of plan to lower drug prices There are still plenty of unanswered questions about Trump's plan to push U.S. drug prices down closer to those in other countries. By Daniel Payne FABRICE COFFRINI/AFP via Getty Images With U.S. absent, WHO adopts pandemic treaty aimed at improving vaccine access Countries at the World Health Assembly showed strong support for the treaty, which was negotiated over three years. By Andrew Joseph Private funder HHMI pauses postdoc fellowship Howard Hughes Medical Institute pauses Hanna Gray fellowship applications. Postdoc funding cuts force young scientists to look for opportunities overseas. By Anil Oza STAT+ | Mental health apps can boost outcomes and lower costs, study finds A Peterson Health Technology Institute report shows mental health apps like Rejoyn and DaylightRx can save money and improve outcomes. By Mario Aguilar Adobe Opinion: I study diet and chronic illness. Here's the uncomfortable truth about seed oils The scientific community has not definitively settled the health effects of high seed oil consumption, writes an expert. By Jane Zhao STAT+ | Maryland governor signs law to expand powers of the state's prescription drug affordability board The new law was criticized by the pharmaceutical industry for pursuing an "unproven" strategy toward lowering expenses. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser